National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4606-4610

  Obritsch, Marilee D ^a   Fish, Douglas N ^a   MacLaren, Robert ^a   Jung, Rose ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DATA BASE; DRUG MONITORING; INTENSIVE CARE UNIT; MEDICAL RECORD; NONHUMAN; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; UNITED STATES;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PRODUCT SURVEILLANCE, POSTMARKETING; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; UNITED STATES;

EID: 9644274002     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4606-4610.2004     Document Type: Article

References (13)

1. Alverez-Lerma, F., et al. 1996. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 22:387-394.
2. Flamm, R. K., M. K. Weaver, C. Thornsberry, M. E. Jones, J. A. Karlowsky, and D. F. Sahm. 2004. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob. Agents Chemother. 48:2431-2436.
3. Gales, A. C., R. N. Jones, J. Turnidge, R. Rennie, and R. Ramphal. 2001. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32:S146-S155.
4. Haley, R. W., D. H. Culver, J. W. White, W. M. Morgan, T. G. Emori, V. P. Munn, and T. M. Hooton. 1985. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am. J. Epidemiol. 121:182-205.
5. Hanberger, H., J. A. Garcia-Rodriguez, M. Gobernado, et al. 1999. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 281:67-71.
6. Ibrahim, E. H., G. Sherman, S. Ward, V. J. Fraser, and M. H. Kollef. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146-155.
7. Itokazu, G. S., J. P. Quinn, C. Bell-Dixon, F. M. Kahan, and R. A. Weinstein. 1996. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin. Infect. Dis. 23:779-784.
8. Kollef, M. H. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
9. Leibovici, L., I. Shraga, M. Drucker, H. Konigsberger, Z. Samra, and S. D. Pitlik. 1998. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J. Intern. Med. 244:379-386.
10. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. National Nosocomial Infections Surveillance System. 1999. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27:520-532.
12. Neuhauser, M. M., R. A. Weinstien, R. Rdyman, L. H. Danziger, G. Karam, and J. P. Quinn. 2003. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 289:885-888.
13. Pfaller, M. A., R. N. Jones, and D. J. Biedenbach. 2001. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn. Microbiol. Infect. Dis. 41:177-182.